NASDAQ : AXSM
Axsome Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 136.01 USD (Nov 2, 2026, 4:00 PM EST) · Market cap 7.12B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.12B |
| Enterprise Value | 7.03B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 52.38M |
| Shares Outstanding | 52.38M |
| Shares Change (YoY) | +4.68% |
| Shares Change (QoQ) | +1.25% |
| Owned by Insiders (%) | 1.06% |
| Owned by Institutions (%) | 75.17% |
| Float | 44.46M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 110.58 |
| PS Ratio | 7.93 |
| Forward PS | 5.21 |
| PB Ratio | 72.02 |
| P/TBV Ratio | 119.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 7.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.42 |
| Quick Ratio | 1.29 |
| Debt / Equity | 2.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.90 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -175.59% |
| Return on Assets (ROA) | -13.65% |
| Return on Invested Capital (ROIC) | -33.13% |
| Return on Capital Employed (ROCE) | -51.53% |
| Weighted Average Cost of Capital (WACC) | 8.83% |
| Revenue Per Employee | $642,844 |
| Profits Per Employee | -$116,859 |
| Employee Count | 1,346 |
| Asset Turnover | 1.16 |
| Inventory Turnover | 1.76 |
Taxes
| Measure | Value |
|---|
| Income Tax | 646,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.85 |
| 52-Week Price Change | +0.76% |
| 50-Day Moving Average | 183.33 |
| 200-Day Moving Average | 199.14 |
| Relative Strength Index (RSI) | 19.96 |
| Average Volume (20 Days) | 1,066,852 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.11M |
| Short Previous Month | 3.31M |
| Short % of Shares Out | 5.94% |
| Short % of Float | 7.00% |
| Short Ratio (days to cover) | 3.67 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 865.27M |
| Gross Profit | 806.85M |
| Operating Income | -163.38M |
| Pretax Income | -156.65M |
| Net Income | -157.29M |
| EBITDA | -152.45M |
| EBIT | -163.38M |
| Loss Per Share | -$3.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 313.86M |
| Total Debt | 218.67M |
| Net Cash | 95.19M |
| Net Cash Per Share | $1.82 |
| Equity (Book Value) | 105.43M |
| Book Value Per Share | 2.01 |
| Working Capital | 214.92M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -71.26M |
| Capital Expenditures | -700,000 |
| Depreciation & Amortization | 10.94M |
| Net Borrowing | -3.09M |
| Free Cash Flow | -71.96M |
| FCF Per Share | -$1.37 |
Margins
| Measure | Value |
|---|
| Gross Margin | 93.25% |
| Operating Margin | -18.88% |
| Pretax Margin | -18.10% |
| Profit Margin | -18.18% |
| EBITDA Margin | -17.62% |
| EBIT Margin | -18.88% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.68% |
| Shareholder Yield | -4.68% |
| Earnings Yield | -2.24% |
| FCF Yield | -1.05% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $277.29 |
| Price Target Difference | 103.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (3Y) | 49.09% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |